Video Health Monitoring in Hospitals (Paperback)
Wenjin Wang
Sold by CitiRetail, Stevenage, United Kingdom
AbeBooks Seller since 29 June 2022
New - Soft cover
Condition: New
Ships from United Kingdom to U.S.A.
Quantity: 1 available
Add to basketSold by CitiRetail, Stevenage, United Kingdom
AbeBooks Seller since 29 June 2022
Condition: New
Quantity: 1 available
Add to basketPaperback. Video Health Monitoring in Hospitals This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
Seller Inventory # 9780443265860
Dr. Wenjin Wang is an Associate Professor in the Department of Biomedical Engineering at SUSTech, a PhD advisor, and the Principal Investigator (PI) of the Contactless Healthcare Lab. His research focuses on contactless health monitoring using camera sensors. Before joining SUSTech, he was an Assistant Professor at Eindhoven University of Technology (TU/e) and a Scientist at Philips Research Eindhoven. He earned his PhD from TU/e in 2017 and his MSc from the University of Amsterdam in 2013 (recipient of the Amsterdam Merit Scholarship, Top 5%). Upon returning to China, he was awarded the National Excellent Young Scholars (Overseas) in 2022.
Dr. Wang is recognized on the Stanford Top 2% Scientists List. In 2023, he was named one of the Top 20 Young Scientists in China by the Journal of Scientific Chinese. In 2024, he received the Young Scientist Innovation Prize from the Guangdong Provincial Government. He has authored 110 SCI journal articles and international conference papers (including IEEE-TBME/JBHI/IOTJ/TIM), accumulating over 4,100 Google Scholar citations. He has received the IEEE-EMBS Prize Paper Award, published 2 Elsevier books, and holds 20 granted US/EP/JP patents and 15 Chinese patents.
His research has been supported by prestigious national and industrial grants, including the National Key R&D Program of China; Original Research Program of Natural Science Foundation of China (NSFC); General Research Program of NSFC; General Program of Guangdong Basic and Applied Basic Research Foundation; General Program of Shenzhen Science and Technology Foundation; Peacock Team Program of Shenzhen; Shenzhen Enterprise Research Program; etc.
An active contributor to the academic community, Dr. Wang co-founded the CVPM Workshop and has organized it annually at CVPR/ICCV. He has been invited to deliver tutorials at CVPR every year from 2019 to 2025. He serves as a Guest Associate Editor for IEEE-JBHI.
Prof. Hongzhou Lu is a leading scientist of internal medicine. He has engaged in the research, education and clinical practice for the infectious diseases, particularly for the functional cure of AIDs since 1988. His working fields include as follows: fever of unknown origin; rational use of antibiotics; infection of the central nervous system; infection of the respiratory system. He finished his undergraduate course in clinical medicine at Bengbu Medical College, and became a M.D. of internal medicine (1988). He obtained his Ph.D degree in internal medicine at Shanghai Medical University (1999), and finished his postdoctoral training at Vanderbilt University Medical Center, TN, USA (2002). After he finished his resident training, he joined the Huashan Hospital of Fudan University, and served as a doctor-in-charge at that hospital. From 2002, after finished his postdoctoral training, he was appointed his first professorship in lemology at Huashan Hospital of Fudan University. From 2012, he relocated to the Shanghai Public Health Clinical Center Affiliated to Fudan University, and became a full professor in lemology as well the director/leader of that hospital till 2021. Then he moved to Shenzhen Third People’s Hospital, Second Hospital Affiliated to Southern University of Science and Technology (SUSTech), National Clinical Research Center for Infectious Diseases. Now he is serving as a full professor in lemology of SUSTech as well as the director/leader of this hospital. He founded an international academic journal iLABMED, and became the Editor-in-Chief in 2023. From 2024, he was selected as the deputy dean of Medical School of SUSTech. He is also serving as a Ph.D/master mentor in Fudan University, SUSTech, and Bengbu Medical University.
Prof. Lu is a distinguished researcher in his fields. He has got over 500 peer-reviewed scientific publications as the first/corresponding author, including the world’s top journals such as NEJM, Nature, and STTT. He published 15 scientific books and obtained 15 patents. He was included as the Stanford University's World's Top 2% Scientists in 2021─2024. He was selected as the top 0.05% highly ranked scholar in both lifetime and prior five years by ScholarGPS (https://scholargps.com/).
As a leading clinician in infectious diseases, Prof. Lu makes outstanding contributions in prevention/control of emerging infectious diseases. He was invited as the member of the national committee of experts in prevention/control of COVID-19, as well as the leader of the committee of experts in Shanghai and Shenzhen. He organized and published many guidelines/ expert consensus against emerging infectious diseases such as COVID-19 and Mpox. He also engaged in research & development of many indigenous innovative drugs, such as oral small-molecule drugs in treating COVID-19, including simnotrelvir and SHEN26 capsule, which efficacy and safety have been strictly verified.
Prof. Lu is an experienced international scientist who is keen on international communication and international cooperation. He has rich experience in carrying out international cooperative research. As a leading expert of China CDC, he was invited to The Republic of Sierra Leone to help this country to fight against Ebola virus in 2014. His enthusiastic service and excellent medical skill were highly praised and respected by the local people in Africa. He has succeeded in carrying out many international cooperative projects. Now he is serving as a co-director of WHO Collaborating Centre for Clinical Management and an expert of WHO Clinical Expert Group.
Professor Nanshan Zhong is national leader in the prevention and treatment of major respiratory infectious diseases, chronic obstructive pulmonary disease, bronchial asthma and other respiratory diseases in China. He has published more than 540 international peer-peer papers (Total citations: 10,800, H-index 50), on world’s top medical journals such as NEJM, Lancet, and JAMA. He also published more than 400 papers in national journals sponsored by the Chinese Medical Association; and various monographs , , he had nearly 60 invention patents. His practical and scientific treatment experience contributed a lot to public health policy shaping of China &Global in every pandemic incident.
During the SARS outbreak in 2003, Prof. Zhong opposed the view that typical chlamydia was the cause of SARS. His expertise provided a scientific basis for treatment decision-making in time. Professor Zhong’s team explored "three earlies and three rations" treatment protocol in a short time, namely, early diagnosis, early isolation, early treatment, rational use of corticosteroids, rational use of ventilators, and rational treatment of comorbidities). This protocol contributed to the 3.3% SARS mortality rate in Guangdong, which was the world's lowest SARS mortality rate.
Professor Zhong has been leading the development of a number of Chinese guidelines for the diagnosis and management of bronchial asthma, COPD, chronic cough, SARS, highly-pathogenic avian influenza and COVID-19. Since March 2020, Professor Zhong has attended more than thirty international webinar meetings on epidemic prevention and control, including the US, the UK, France, Germany, Italy, Spain, Canada, Japan, Korea, India, Iraq and Nepal. The meetings aimed to share the Chinese experience to help these countries to deal with COVID-19 epidemic. He has also called for greater attention to the spread of novel coronavirus in a number of countries, addressing the importance of implementing the “Four Earlies” principles: early protection, early detection, early diagnosis, and early isolation. In September 2020, he was nominated as a member of COVID-19 Independent Panel for Pandemic Preparedness and Response, WHO.
Professor Zhong, shouldering the responsibilities in the outbreak of three coronavirus events this century, has made great efforts in clinical diagnosis, medication, scientific research and governmental strategies. He proposes “One world, one fight” to gather all the resources and strength to fight against the epidemic.
Albertus C. den Brinker received the M.Sc. degree in electrical engineering in 1983 from Eindhoven University of Technology (TU/e). In 1989, he received the Ph.D. degree for his work on dynamic models of the human visual system.
From 1987 to 1999 he worked in the Signal Processing Group at the Department of Electrical Engineering, at Eindhoven University of Technology. His educational activities included electrical network theory and digital filter theory. His research activities concerned diverse topics from fields like approximation, identification, digital signal processing and applications of orthogonal series expansions to (local) signal analysis and adaptive filtering.
In 1999, he joined the Philips Research Laboratories Eindhoven. Activities included audio and speech coding, standardization, and classification and interpretation of audio signals. Later, healthcare applications were the main topics, in particular contactless monitoring of patients. He retired from Philips at the end of 2023.
Dr. den Brinker publishes regularly in international scientific journals and proceedings of scientific conferences and is (co-)author of various patents.
"About this title" may belong to another edition of this title.
Orders can be returned within 30 days of receipt.
If you are a consumer you can withdraw from the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.
Information regarding the right of withdrawal
Statutory right to withdraw
You have the right to withdraw from this contract within 14 days without giving any reason.
The withdrawal period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the last good or the last lot or piece.
To exercise the right of withdrawal, electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". We will communicate to you an acknowledgement of receipt of such a withdrawal on a durable medium (e.g. by e-mail) without delay.
To meet the withdrawal deadline, it is sufficient for you to send your communication concerning your exercise of the right of withdrawal before the withdrawal period has expired.
Effects of withdrawal
If you withdraw from this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).
We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.
We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to withdraw from this contract.
We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.
We may withhold reimbursement until we have received the goods back, or you have supplied evidence of having sent back the goods, whichever is the earliest.
You shall send back the goods or hand them over to CitiRetail, Stevenage, United Kingdom, without undue delay and in any event not later than 14 days from the day on which you communicate your withdrawal from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.
Exceptions to the right of withdrawal
The right of withdrawal does not apply to:
Please note that titles are dispatched from our US, Canadian or Australian warehouses. Delivery times specified in shipping terms. Orders ship within 2 business days. Delivery to your door then takes 7-14 days.
| Order quantity | 7 to 60 business days | 7 to 14 business days |
|---|---|---|
| First item | £ 37.00 | £ 37.00 |
Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.